Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business fundraising

ByteDance Anew Labs $290M AI Drug Spin-off

Analysis based on 6 articles · First reported Sep 16, 2026 · Last updated Sep 16, 2026

Sentiment
25
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The deal signals continued investor appetite for specialized AI applications in China, particularly in capital-intensive scientific fields, and provides a fresh valuation benchmark for AI drug discovery ventures. It modestly supports sentiment toward Chinese AI and biotech investment while highlighting that ByteDance is building an AI portfolio beyond consumer internet, though the $1.5 billion valuation rests on unapproved drug candidates and years-long development timelines.

artificial intelligence pharmaceuticals venture capital

ByteDance completed a $290 million inaugural external fundraising for Anew Labs, its newly spun-off AI drug discovery unit based in China — Shanghai, valuing the business at $1.5 billion, according to two sources familiar with the matter. The round was led by HSG (formerly Sequoia China), IDG Capital and Hillhouse Investment, with 5Y Capital as co-lead investor. Other participants included Gaorong Ventures, Primavera Capital Group, Boyu Capital, strategic investor SBP Group and the state-backed Shanghai Future Industries Fund. ByteDance retains a 56% stake in Anew Labs after the round. ByteDance separated the unit because AI-driven drug discovery follows a different industry logic, longer development cycles and a different management approach than its core consumer internet operations. Anew Labs has operations in China — Shanghai, Singapore and United States — California, and its team is headed by Liu Kai, who previously spent seven years in venture capital at IDG Capital and Fire Stone Investment before joining ByteDance in 2021. Volcano Engine, ByteDance's cloud division, will continue to provide computing power. The unit has developed structure-prediction and protein-design models such as Protenix and PXDesign and holds four drug candidates, including an AI-designed IL-17 inhibitor presented by Chris Li, head of biology, at a meeting of the American Association of Immunologists in Boston in April. The spin-off was first reported by SBM Intelligence, a 36Kr publication, which said roughly 50 core staff would move to the new company along with algorithms, technology platform and pipeline assets. ByteDance, owner of ByteDance — TikTok Shop, TikTok and CapCut, and the investors did not immediately respond to requests for comment.

95 Anew Labs raised $290 million
75 ByteDance spun off Anew Labs
70 HSG led fundraising Anew Labs
65 IDG Capital led fundraising Anew Labs
65 Hillhouse Investment led fundraising Anew Labs
55 5Y Capital co-led fundraising Anew Labs
45 Boyu Capital invested Anew Labs
45 SBP Group invested Anew Labs
30 Volcano Engine provided computing power Anew Labs
25 Chris Li presented AI-designed inhibitor American Association of Immunologists
priv
The China — Shanghai-based AI drug discovery unit raised $290 million at a $1.5 billion valuation in its first external round, giving it capital and independence to develop its models and four drug candidates.
Importance 100.0 Sentiment 40.0
priv
ByteDance spun off Anew Labs and retains a 56% stake, monetizing an AI drug-discovery asset while keeping majority control and sharing the financing burden with external investors.
Importance 95.0 Sentiment 30.0
priv
The firm formerly known as Sequoia China led the $290 million round, deepening its exposure to Chinese AI-driven drug discovery.
Importance 70.0 Sentiment 20.0
priv
IDG Capital co-led the fundraising and is the former employer of Anew Labs head Liu Kai, reinforcing its ties to the venture.
Importance 65.0 Sentiment 20.0
priv
Hillhouse Investment co-led the round, adding a major Chinese private-equity name to Anew Labs' investor base.
Importance 65.0 Sentiment 20.0
priv
5Y Capital acted as co-lead investor in the inaugural external round for Anew Labs.
Importance 55.0 Sentiment 15.0
priv
Gaorong Ventures participated as an investor in the $290 million round.
Importance 45.0 Sentiment 10.0
priv
Primavera Capital Group participated as an investor in the $290 million round.
Importance 45.0 Sentiment 10.0
priv
Boyu Capital participated as an investor in the $290 million round.
Importance 45.0 Sentiment 10.0
priv
The state-backed fund invested in the round, signaling official support for AI drug discovery in China — Shanghai.
Importance 45.0 Sentiment 10.0
priv
SBP Group joined the round as a strategic investor, potentially bringing industry networks to Anew Labs.
Importance 40.0 Sentiment 10.0
per
Liu Kai heads the Anew Labs team; his prior seven years in venture capital at IDG Capital and Fire Stone Investment link the unit to its new investors.
Importance 40.0 Sentiment 10.0
cnt
China is the home market of ByteDance and Anew Labs, and the deal adds to evidence of Chinese investment shifting toward specialized AI applications.
Importance 35.0 Sentiment 10.0
priv
ByteDance's cloud division will continue to provide computing power to Anew Labs, keeping the unit tied to ByteDance infrastructure.
Importance 30.0 Sentiment 10.0
loc
China — Shanghai is the headquarters of Anew Labs and home to the state-backed Shanghai Future Industries Fund that invested in the round.
Importance 30.0 Sentiment 10.0
+ 13 more entities View on Dashboard
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.